“…Whether QFT-GIT is an essential biomarker of preventive treatment efficacy remains controversial (Bastos et al, 2013;Cranmer et al, 2018;Goletti et al, 2018;Goletti et al, 2007;Kabeer et al, 2011;Takenami et al, 2012). In addition, the occurrence of reversion and conversion of IGRA results has been reported in cohort studies of untreated LTBI (Adams et al, 2015;Adetifa et al, 2013;Aichelburg et al, 2014;Andrews et al, 2015;Bartalesi et al, 2013;Chiappini et al, 2012;Lee et al, 2012;Monárrez-Espino et al, 2014;Moucaut et al, 2013;Shu et al, 2016;Uto et al, 2014;Zwerling et al, 2013). Hence, larger-scale trials are required to validate the use of serial QFT-GIT tests for evaluating the efficacy of preventive treatment.…”